<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="700">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844632</url>
  </required_header>
  <id_info>
    <org_study_id>COVID19 vaccination_Sapienza</org_study_id>
    <nct_id>NCT04844632</nct_id>
  </id_info>
  <brief_title>COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring</brief_title>
  <acronym>SAPIENZAVAX</acronym>
  <official_title>COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Superiore di Sanità</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      1. Monitor adverse events (Adverse Event Following Immunization - AEFI) in vaccinated&#xD;
      subjects and analyze the associations with: (a) demographic variables and anthropometric&#xD;
      parameters (sex, age, BMI, etc.); (b) socioeconomic-cultural variables; (c) co-morbidities.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. Monitor the antibody response in vaccinated subjects and analyze the associations with:&#xD;
           (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.); (b)&#xD;
           socioeconomic-cultural variables; (c) co-morbidities.&#xD;
&#xD;
        2. Assess the quantity (antibody titer) and quality of the anti-Spike immune response&#xD;
           induced by vaccination.&#xD;
&#xD;
        3. Evaluate the dynamics of the infection and the protective efficacy of the vaccine&#xD;
           against infection / disease by studying the incidence and titre of antibodies against&#xD;
           Nucleoprotein (N) induced by natural infection;&#xD;
&#xD;
        4. Evaluate the neutralizing capacity of sera vs. a panel of sera selected and analyzed in&#xD;
           house and in in vitro microneutralization systems with live virus;&#xD;
&#xD;
        5. To evaluate the cell-mediated immune response (CMI) to vaccination against SARS-CoV-2 in&#xD;
           a subgroup of vaccinees.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
        1. Administration at baseline of a questionnaire for the collection of clinical data.&#xD;
&#xD;
        2. Perform a blood sample to measure antibody response in vaccinated subjects&#xD;
&#xD;
        3. Administer a questionnaire to evaluate adverse events after vaccination&#xD;
&#xD;
        4. Reassess the antibody response 1 month after complete vaccination and 6 and 12 months&#xD;
           after the start of vaccination&#xD;
&#xD;
        5. An antibody assay will be drawn in a subgroup before subjecting the subject to the&#xD;
           vaccine.&#xD;
&#xD;
        6. In a subgroup, the blood collected will also be collected in a heparinized tube for the&#xD;
           study of cell-mediated immunity.&#xD;
&#xD;
        7. In the event that a subject participating in the study presents during the course of the&#xD;
           observation the positivity for the molecular research of SARS-CoV-2 RNA to the&#xD;
           oro-nasopharyngeal swab, a new sample will be performed and sent to the Istituto&#xD;
           Superiore di Sanità for the search for viral variants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">May 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Following Immunization - AEFI</measure>
    <time_frame>12 months from immunization</time_frame>
    <description>Adverse events (Adverse Event Following Immunization - AEFI) monitoring in vaccinated subjects and analyze associations with: (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.); (b) socioeconomic-cultural variables; (c) co-morbidities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response in vaccinated subject</measure>
    <time_frame>1, 3, 6, 12 months from immunization</time_frame>
    <description>To monitor the antibody response in vaccinated subjects and analyze the associations with: (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.); (b) socioeconomic-cultural variables; (c) co-morbidities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Spike immune response</measure>
    <time_frame>1, 3, 6, 12 months from immunization</time_frame>
    <description>Assess the quantity (antibody titer) and quality of the anti-Spike immune response induced by vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti- Nucleoprotein (N) induced by natural infection evaluation</measure>
    <time_frame>1, 3, 6, 12 months from immunization</time_frame>
    <description>To assess the dynamics of the infection and the protective efficacy of the vaccine against infection / disease by studying the incidence and titre of antibodies against Nucleoprotein (N) induced by natural infection;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing capacity of sera</measure>
    <time_frame>1, 3, 6, 12 months from immunization</time_frame>
    <description>to evaluate the neutralizing capacity of sera vs. a panel of sera selected and analyzed in house and in in vitro microneutralization systems with live virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immune response</measure>
    <time_frame>Time 0 (before immunization) 3, 10, 21, 30 days; 1, 3, 6 months from immunization</time_frame>
    <description>To evaluate the cell-mediated immune response (CMI) to vaccination against SARS-CoV-2 in a subgroup of vaccinees.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Health Care Utilization</condition>
  <condition>Health Care Associated Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccine anti-Covid19</intervention_name>
    <description>Vaccination with AstraZeneca or Pfizer-Biontech anti-Covid19 vaccine</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects (age&gt; 18) booked for anti-SARS-CoV-2 vaccination at the AOU Policlinico Umberto I.&#xD;
&#xD;
        Subjects will include healthcare personnel, medical students and university staff recruited&#xD;
        from Sapienza University of Rome and Umberto I university hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects vaccinated or to be vaccinated at the AOU Policlinico Umberto I and who will&#xD;
        agree to join the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects who refuse to give consent or who have contraindications to vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefania Basili, MD</last_name>
    <phone>+393393452523</phone>
    <email>stefania.basili@uniroma1.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Basili, MD</last_name>
      <email>stefania.basili@uniroma1.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Stefania Basili</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

